Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while ...

More than half of severe COVID-19 survivors show fibrotic-like lung abnormalities even 3 years after infection, especially ...

By Dr. Sanchari Sinha Dutta, Ph.D. A simple at-home program with daily exercise, airway clearance, and nurse support helps ...

When she began experiencing frequent bouts of infection, she was still told it was down to “poorly controlled asthma”.A respiratory consultant said the results of a CT scan showed signs of ...

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin ...

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially ...

The drug also is being studied as a possible treatment for another chronic respiratory problem that gets worse over time: non ...

Paediatric-onset bronchiectasis leads to more severe disease than adult-onset, highlighting need for early, tailored care.

The bronchiectasis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM bronchiectasis market size from 2020 to ...

The FDA is expected to decide on treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis.

—Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo ...